Iproclozide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Iproclozide
Accession Number
DB09247
Type
Small Molecule
Groups
Withdrawn
Description

Iproclozide is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued. It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.

Structure
Thumb
Synonyms
Not Available
External IDs
PC-603
International/Other Brands
Sinderesin / Sursum
Categories
UNII
1II9D6CB3J
CAS number
3544-35-2
Weight
Average: 242.7
Monoisotopic: 242.0822054
Chemical Formula
C11H15ClN2O2
InChI Key
GGECDTUJZOXAAR-UHFFFAOYSA-N
InChI
InChI=1S/C11H15ClN2O2/c1-8(2)13-14-11(15)7-16-10-5-3-9(12)4-6-10/h3-6,8,13H,7H2,1-2H3,(H,14,15)
IUPAC Name
2-(4-chlorophenoxy)-N'-(propan-2-yl)acetohydrazide
SMILES
CC(C)NNC(=O)COC1=CC=C(Cl)C=C1

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Iproclozide.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Iproclozide.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Iproclozide.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Iproclozide.Experimental, Illicit
4-MethoxyamphetamineIproclozide may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Iproclozide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineIproclozide may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Abediterol.Investigational
AcarboseIproclozide may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololIproclozide may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Iproclozide.Experimental
AlbiglutideIproclozide may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Iproclozide.Approved, Illicit
AliskirenIproclozide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Iproclozide.Approved, Investigational
AlogliptinIproclozide may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Iproclozide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Iproclozide.Illicit
AlprenololIproclozide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Iproclozide.Approved
AmbrisentanIproclozide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineIproclozide may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineIproclozide may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideIproclozide may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineIproclozide may increase the hypotensive activities of Amlodipine.Approved
AmoxapineIproclozide may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Iproclozide.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Iproclozide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Arformoterol.Approved, Investigational
AtenololIproclozide may increase the hypotensive activities of Atenolol.Approved
AtomoxetineIproclozide may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineIproclozide may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bambuterol.Approved, Investigational
BenazeprilIproclozide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIproclozide may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Iproclozide.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Iproclozide.Approved, Illicit
BepridilIproclozide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Iproclozide.Approved, Investigational
BetaxololIproclozide may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineIproclozide may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bezafibrate.Approved, Investigational
BietaserpineIproclozide may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostIproclozide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIproclozide may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bitolterol.Withdrawn
BosentanIproclozide may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Iproclozide may increase the hypotensive activities of BQ-123.Investigational
BretyliumIproclozide may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Iproclozide.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Brimonidine.Approved
BrofaromineIproclozide may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Iproclozide.Approved, Investigational
BupranololIproclozide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproclozide.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Iproclozide is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iproclozide.Approved, Illicit, Vet Approved
ButriptylineIproclozide may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Iproclozide.Approved
CadralazineIproclozide may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIproclozide may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinIproclozide may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanIproclozide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilIproclozide may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilIproclozide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIproclozide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproclozide.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Iproclozide.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Iproclozide.Approved, Investigational
CaroxazoneIproclozide may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololIproclozide may increase the hypotensive activities of Carteolol.Approved
CarvedilolIproclozide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololIproclozide may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideIproclozide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Iproclozide.Illicit, Withdrawn
ChlorpropamideIproclozide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneIproclozide may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIproclozide may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIproclozide may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Iproclozide.Approved, Investigational
CirazolineIproclozide may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Iproclozide.Approved
ClemastineIproclozide may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineIproclozide may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineIproclozide may increase the hypertensive activities of Clonidine.Approved
CloranololIproclozide may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Iproclozide.Approved, Illicit
CryptenamineIproclozide may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Iproclozide.Approved
CyclopenthiazideIproclozide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIproclozide may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineIproclozide may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinIproclozide may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Iproclozide.Investigational
DebrisoquinIproclozide may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilIproclozide may increase the hypotensive activities of Delapril.Investigational
DeserpidineIproclozide may increase the hypotensive activities of Deserpidine.Approved
DesipramineIproclozide may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iproclozide.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateIproclozide may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Iproclozide.Approved, Illicit
DextromethorphanIproclozide may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iproclozide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iproclozide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Iproclozide.Approved, Investigational
DiazoxideIproclozide may increase the hypotensive activities of Diazoxide.Approved
DibenzepinIproclozide may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineIproclozide may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionIproclozide may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineIproclozide may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iproclozide.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Iproclozide.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iproclozide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iproclozide.Experimental, Illicit
DiltiazemIproclozide may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineIproclozide may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iproclozide.Approved, Illicit
DipivefrinIproclozide may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideIproclozide may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Iproclozide is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Iproclozide is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideIproclozide may increase the hypotensive activities of Dorzolamide.Approved
DosulepinIproclozide may increase the serotonergic activities of Dosulepin.Approved
DoxapramIproclozide may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinIproclozide may increase the hypotensive activities of Doxazosin.Approved
DoxepinIproclozide may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Doxofylline.Approved, Investigational
DoxylamineIproclozide may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Iproclozide.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Iproclozide.Experimental, Illicit
DroxidopaIproclozide may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideIproclozide may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Iproclozide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Iproclozide.Experimental, Illicit
EfonidipineIproclozide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Iproclozide.Approved, Investigational
EmpagliflozinIproclozide may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilIproclozide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIproclozide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIproclozide may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproclozide.Approved, Investigational
EpanololIproclozide may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Iproclozide is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineIproclozide may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolIproclozide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIproclozide may increase the hypotensive activities of Eprosartan.Approved
ErgonovineIproclozide may increase the hypertensive activities of Ergonovine.Approved
ErgotamineIproclozide may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Iproclozide.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproclozide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iproclozide.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Iproclozide.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Iproclozide.Illicit, Vet Approved
ExenatideIproclozide may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineIproclozide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineIproclozide may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamIproclozide may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iproclozide.Approved, Illicit, Investigational, Vet Approved
Ferulic acidIproclozide may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Iproclozide.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Iproclozide.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Iproclozide.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Formoterol.Approved, Investigational
FosinoprilIproclozide may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Iproclozide.Approved, Investigational
FurazolidoneIproclozide may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Iproclozide.Experimental
GliclazideIproclozide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIproclozide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIproclozide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideIproclozide may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzIproclozide may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelIproclozide may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIproclozide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIproclozide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIproclozide may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorIproclozide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIproclozide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIproclozide may increase the hypotensive activities of Guanoxan.Experimental
HarmalineIproclozide may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Iproclozide.Approved, Illicit, Investigational
HexamethoniumIproclozide may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the hypertensive activities of Iproclozide.Experimental
HydralazineIproclozide may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIproclozide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Iproclozide.Approved, Illicit
HydroflumethiazideIproclozide may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iproclozide.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Iproclozide.Approved
ImidaprilIproclozide may increase the hypotensive activities of Imidapril.Investigational
ImipramineIproclozide may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Iproclozide.Investigational, Withdrawn
IndapamideIproclozide may increase the hypotensive activities of Indapamide.Approved
IndenololIproclozide may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIproclozide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartIproclozide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIproclozide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIproclozide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIproclozide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIproclozide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIproclozide may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Iproclozide.Approved
IprindoleIproclozide may increase the serotonergic activities of Iprindole.Experimental
IproniazidIproniazid may increase the hypertensive activities of Iproclozide.Withdrawn
IrbesartanIproclozide may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Iproclozide.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Iproclozide is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Isoprenaline.Approved, Investigational
IsradipineIproclozide may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinIproclozide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iproclozide.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iproclozide.Approved, Nutraceutical, Withdrawn
LabetalolIproclozide may increase the hypotensive activities of Labetalol.Approved
LacidipineIproclozide may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostIproclozide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIproclozide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproclozide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iproclozide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Iproclozide.Approved, Investigational
LevonordefrinIproclozide may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iproclozide.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Iproclozide is combined with Linezolid.Approved, Investigational
LinsidomineIproclozide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideIproclozide may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Iproclozide.Approved, Investigational
LisinoprilIproclozide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Iproclozide.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Iproclozide is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Iproclozide.Illicit
LofepramineIproclozide may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Iproclozide.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Iproclozide.Approved
LosartanIproclozide may increase the hypotensive activities of Losartan.Approved
MacitentanIproclozide may increase the hypotensive activities of Macitentan.Approved
ManidipineIproclozide may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Maprotiline.Approved, Investigational
MebanazineIproclozide may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineIproclozide may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminIproclozide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenIproclozide may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Iproclozide.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Iproclozide.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Iproclozide.Experimental
MequitazineIproclozide may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolIproclozide may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminIproclozide may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Iproclozide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Iproclozide.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Iproclozide.Approved, Illicit
MethoserpidineIproclozide may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineIproclozide may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Iproclozide.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Iproclozide is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Iproclozide.Experimental
Methylene blueIproclozide may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateIproclozide may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Iproclozide.Approved
MetipranololIproclozide may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIproclozide may increase the hypotensive activities of Metolazone.Approved
MetoprololIproclozide may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIproclozide may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Iproclozide is combined with Mianserin.Approved, Investigational
MibefradilIproclozide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineIproclozide may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Iproclozide.Experimental, Illicit, Investigational
MifepristoneIproclozide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIproclozide may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Iproclozide.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Iproclozide.Approved
MinoxidilIproclozide may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Iproclozide.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Moclobemide.Approved, Investigational
MoexiprilIproclozide may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Iproclozide.Approved, Investigational
MoxonidineIproclozide may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineIproclozide may increase the hypotensive activities of Muzolimine.Experimental
NadololIproclozide may increase the hypotensive activities of Nadolol.Approved
NaftopidilIproclozide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iproclozide.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Iproclozide.Investigational
NaphazolineIproclozide may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Iproclozide.Approved, Investigational
NateglinideIproclozide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololIproclozide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Iproclozide.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Iproclozide.Withdrawn
NicardipineIproclozide may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilIproclozide may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineIproclozide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIproclozide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineIproclozide may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineIproclozide may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIproclozide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideIproclozide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineIproclozide may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Iproclozide.Approved, Illicit
NortriptylineIproclozide may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinIproclozide may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineIproclozide may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanIproclozide may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Olodaterol.Approved
OmapatrilatIproclozide may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolIproclozide may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Iproclozide.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Orciprenaline.Approved
OxprenololIproclozide may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Iproclozide is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineIproclozide may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproclozide.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Iproclozide.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Iproclozide.Approved, Investigational
PenbutololIproclozide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineIproclozide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iproclozide.Approved, Vet Approved
PentoliniumIproclozide may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Iproclozide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilIproclozide may increase the hypotensive activities of Perindopril.Approved
PethidineIproclozide may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Iproclozide is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Iproclozide.Experimental
PhendimetrazineIproclozide may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Iproclozide.Approved
PheniprazineIproclozide may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Iproclozide.Experimental
PhenoxybenzamineIproclozide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineIproclozide may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Iproclozide.Approved, Illicit
PhentolamineIproclozide may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIproclozide may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Iproclozide.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Iproclozide.Investigational
PinacidilIproclozide may increase the hypotensive activities of Pinacidil.Approved
PindololIproclozide may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneIproclozide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Iproclozide.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Iproclozide.Approved
PivhydrazineIproclozide may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenIproclozide may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorIproclozide may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideIproclozide may increase the hypotensive activities of Polythiazide.Approved
PramlintideIproclozide may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinIproclozide may increase the hypotensive activities of Prazosin.Approved
ProcaineIproclozide may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineIproclozide may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Procaterol.Approved, Investigational
PropranololIproclozide may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Protokylol.Approved, Vet Approved
ProtriptylineIproclozide may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Iproclozide.Approved
QuinaprilIproclozide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineIproclozide may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineIproclozide may increase the hypertensive activities of Racepinephrine.Approved
RamiprilIproclozide may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Iproclozide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iproclozide.Approved
RemikirenIproclozide may increase the hypotensive activities of Remikiren.Approved
RepaglinideIproclozide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineIproclozide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Reserpine.Approved, Investigational
RilmenidineIproclozide may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatIproclozide may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Iproclozide.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Iproclozide.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Iproclozide.Approved, Investigational
RosiglitazoneIproclozide may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Iproclozide.Approved
SafrazineIproclozide may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Salmeterol.Approved
SaprisartanIproclozide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinIproclozide may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Iproclozide.Approved, Investigational, Vet Approved
SelexipagIproclozide may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Iproclozide.Approved
SitagliptinIproclozide may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanIproclozide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilIproclozide may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iproclozide.Approved, Investigational
SulfadiazineIproclozide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleIproclozide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIproclozide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Iproclozide.Approved, Investigational
SunitinibIproclozide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololIproclozide may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproclozide.Approved
TelmisartanIproclozide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIproclozide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Terbutaline.Approved
TerlipressinIproclozide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Iproclozide is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Iproclozide.Investigational
TetrahydropalmatineIproclozide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineIproclozide may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineIproclozide may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Iproclozide.Approved, Investigational
TiboloneIproclozide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenIproclozide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Iproclozide.Experimental
TimololIproclozide may increase the hypotensive activities of Timolol.Approved
TolazamideIproclozide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineIproclozide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideIproclozide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproclozide.Approved, Withdrawn
TolonidineIproclozide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Iproclozide.Approved
TorasemideIproclozide may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Iproclozide.Approved, Investigational
TrandolaprilIproclozide may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Iproclozide.Approved, Investigational
TravoprostIproclozide may increase the hypotensive activities of Travoprost.Approved
TrazodoneIproclozide may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilIproclozide may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideIproclozide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinIproclozide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIproclozide may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineIproclozide may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneIproclozide may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilIproclozide may increase the hypotensive activities of Urapidil.Investigational
ValsartanIproclozide may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iproclozide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Iproclozide.Approved
VilanterolThe risk or severity of adverse effects can be increased when Iproclozide is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Iproclozide.Approved
VincamineIproclozide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIproclozide may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Iproclozide.Approved, Investigational
XipamideIproclozide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIproclozide may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Iproclozide.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Iproclozide.Approved
ZofenoprilIproclozide may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Iproclozide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Suerinck A, Suerinck E: [Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]. J Med Lyon. 1966 Apr 5;47(96):573-86. [PubMed:5930723]
  2. Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP: Iproclozide fulminant hepatitis. Possible role of enzyme induction. Gastroenterology. 1978 Sep;75(3):492-6. [PubMed:680506]
External Links
KEGG Drug
D07338
PubChem Compound
19063
PubChem Substance
310265150
ChemSpider
17998
ChEBI
134988
ChEMBL
CHEMBL91238
Wikipedia
Iproclozide
ATC Codes
N06AF06 — Iproclozide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.2 mg/mLALOGPS
logP1.91ALOGPS
logP1.79ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)11.58ChemAxon
pKa (Strongest Basic)3.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.21 m3·mol-1ChemAxon
Polarizability25.21 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Carboxylic acid hydrazides / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Carboxylic acid hydrazide / Carboxylic acid derivative
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 16:25 / Updated on July 02, 2018 19:13